e-learning
resources
Virtual 2020
Pre-Congress Content
Prognosis and biomarkers of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential new biomarkers for idiopathic pulmonary fibrosis
M. Roksandic Milenkovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), V. Ceriman (Belgrade, Republic of Serbia), V. Milenkovic (Belgrade, Republic of Serbia), D. Jovanovic (Belgrade, Republic of Serbia)
Source:
Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session:
Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
817
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Roksandic Milenkovic (Belgrade, Republic of Serbia), J. Kotur Stevuljevic (Belgrade, Republic of Serbia), V. Ceriman (Belgrade, Republic of Serbia), V. Milenkovic (Belgrade, Republic of Serbia), D. Jovanovic (Belgrade, Republic of Serbia). Potential new biomarkers for idiopathic pulmonary fibrosis. 817
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Possible target genes in idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases
Year: 2007
Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (3) 00019-2016; 10.1183/23120541.00019-2016
Year: 2017
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Validation of a novel prognostic tool for idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip
Source: ERS Lung Science Conference 2021
Year: 2021
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
IGFBP-2 a new interesting target in IPF
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (1) 1700379; 10.1183/13993003.00379-2017
Year: 2017
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
Evaluating disease severity in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept